Tim Spelman, Gabrielle Simoneau, Robert Hyde, Robert Kuhelj, Raed Alroughani, Serkan Ozakbas, Rana Karabudak, Bassem I Yamout, Samia J Khoury, Murat Terzi, Cavit Boz, Dana Horakova, Eva Kubala Havrdova, Bianca Weinstock-Guttman, Francesco Patti, Ayse Altintas, Saloua Mrabet, Riadh Gouider, Jihad Inshasi, Vahid Shaygannejad, Sara Eichau, W Luke Ward, Helmut Butzkueven
BACKGROUND AND OBJECTIVES: Patients with pediatric-onset multiple sclerosis (POMS) typically experience higher levels of inflammation with more frequent relapses, and though patients with POMS usually recover from relapses better than adults, patients with POMS reach irreversible disability at a younger age than adult-onset patients. There have been few randomized, placebo-controlled clinical trials of multiple sclerosis (MS) disease-modifying therapies (DMTs) in patients with POMS, and most available data are based on observational studies of off-label use of DMTs approved for adults...
April 9, 2024: Neurology